Last updated: September 1, 2026
Acetaminophen and ibuprofen sodium is a dual-analgesic combination positioned primarily as an intravenous hospital product in the United States and as an oral consumer-health combination in several international markets. The U.S. IV product, marketed as Combogesic IV, combines 1,000 mg of acetaminophen with 300 mg of ibuprofen per 100 mL vial. Its commercial opportunity is based on hospital pain and fever management, reduced reliance on opioids, and convenience from using two non-opioid analgesics in one infusion.[1]
The financial outlook is positive but constrained by hospital formulary adoption, injectable manufacturing costs, established single-agent competitors, and limited public disclosure of product-level sales. The molecule components are mature and generic. Value resides in the fixed-dose formulation, FDA approval, manufacturing capability, and commercial access.
What is acetaminophen and ibuprofen sodium?
Acetaminophen and ibuprofen sodium are non-opioid analgesics with different pharmacologic mechanisms. Acetaminophen is commonly used for pain and fever, while ibuprofen is a nonsteroidal anti-inflammatory drug, or NSAID, with analgesic, antipyretic and anti-inflammatory activity.
The combination is intended to provide additive analgesia without using an opioid. The intravenous formulation is used when oral administration is not suitable.
| Attribute |
U.S. IV combination |
| Brand |
Combogesic IV |
| Active ingredients |
Acetaminophen and ibuprofen sodium |
| Strength |
1,000 mg acetaminophen plus 300 mg ibuprofen per 100 mL |
| Route |
Intravenous infusion |
| U.S. regulatory pathway |
New drug application |
| Indication |
Short-term management of acute pain and reduction of fever |
| Commercial setting |
Hospitals, surgery centers and inpatient care |
| Primary developer |
Hyloris Pharmaceuticals with AFT Pharmaceuticals |
| U.S. commercial partner |
Hikma Pharmaceuticals |
| Key competing products |
OFIRMEV, Caldolor, generic IV acetaminophen and generic IV ibuprofen |
The product is dosed every six hours in adults, subject to maximum daily limits and patient-specific restrictions. The FDA label includes warnings related to hepatic toxicity from acetaminophen and gastrointestinal, renal and cardiovascular risks associated with ibuprofen.[1]
What FDA regulatory status does Combogesic IV have?
The FDA approved the acetaminophen and ibuprofen injection in 2023. The approval created a U.S. regulatory position for a fixed-dose IV combination rather than a new chemical entity.[1]
The product’s regulatory value comes from combining two established active ingredients in one ready-to-use presentation. This can support hospital protocols that seek to reduce opioid exposure, simplify administration and use multimodal analgesia.
FDA approval does not guarantee formulary inclusion. Hospitals generally assess:
- Comparative efficacy against IV acetaminophen and IV ibuprofen
- Total treatment cost
- Pharmacy and nursing workflow
- Infusion volume and administration time
- Renal, hepatic, gastrointestinal and cardiovascular contraindications
- Availability of generic single-agent alternatives
- Contracting terms with group purchasing organizations
The FDA approval also does not create biologic exclusivity. The product is a small-molecule injectable combination and faces generic competition through the abbreviated new drug application, or ANDA, framework if a competitor can satisfy the applicable pharmaceutical equivalence, bioequivalence and manufacturing requirements.
When does acetaminophen and ibuprofen sodium lose exclusivity?
The active ingredients have no meaningful composition-of-matter exclusivity. Acetaminophen and ibuprofen are long-established generic medicines.
Potential exclusivity therefore depends on:
- Any patent covering the fixed-dose formulation or manufacturing process.
- FDA-granted regulatory exclusivity associated with the approved application.
- Patent term adjustment or patent term extension, if applicable.
- The commercial enforceability of any Orange Book-listed patents.
- The ability of a competitor to develop a pharmaceutically equivalent injectable product.
The public commercial case is primarily formulation-based rather than molecule-based. A competitor may be able to design around a formulation patent by changing excipients, concentration, packaging, infusion characteristics or manufacturing conditions.
For the U.S. product, current patent and exclusivity status should be determined from the FDA Orange Book entry for the approved NDA and the applicable FDA patent listing. The Orange Book is the controlling public source for listed patents, expiration dates and approved-use information.[2]
What patents protect acetaminophen and ibuprofen sodium?
The relevant patent estate is expected to focus on the combination product rather than the individual ingredients.
Formulation patents
Formulation claims may cover:
- The relative quantity of acetaminophen and ibuprofen sodium
- Solubilization and pH control
- Stability in aqueous solution
- Prevention of precipitation or crystallization
- Compatibility with infusion containers
- Storage conditions and shelf life
- Ready-to-use or low-volume injectable presentations
These claims can be commercially important because an IV combination must remain stable through manufacturing, shipping, storage and administration. A competitor may avoid infringement by using a different concentration, buffer system or presentation.
Manufacturing patents
Manufacturing protection may cover:
- Dissolution sequence
- Temperature control
- Sterile filtration
- Aseptic filling
- Container closure systems
- Control of degradation products
- Methods for maintaining product stability
Manufacturing patents are more valuable when the process is difficult to reproduce at commercial scale. They are less effective if a competitor can achieve the same product quality through a non-infringing process.
Method-of-use patents
Method-of-use claims may cover administration of the combination for acute pain or fever, including use in patients who cannot take oral medication. Their practical value depends on claim scope and whether a generic applicant can obtain approval with a label that omits the patented use.
Skinny-label strategies can reduce exposure to method-of-use patents, although hospitals and prescribers may still use the product for the patented indication. Litigation risk depends on the specific patent claims and the product label.
How strong is the patent estate for the combination?
The patent estate is moderate rather than dominant.
| Patent value factor |
Assessment |
| Active-ingredient patent protection |
None of commercial significance |
| Fixed-dose formulation |
Potentially meaningful |
| Injectable manufacturing |
Meaningful if process complexity is high |
| Regulatory barrier |
Moderate |
| Generic substitution risk |
Moderate to high over the long term |
| Biosimilar risk |
Not applicable |
| Hospital switching risk |
High relative to patented specialty drugs |
| Dependence on commercial execution |
High |
The product has a more defensible position than an ordinary oral acetaminophen or ibuprofen tablet because sterile injectable manufacturing is technically demanding. It has a weaker position than a product protected by a new chemical entity patent, a biologic patent portfolio or a highly differentiated delivery platform.
Which companies compete with acetaminophen and ibuprofen sodium?
The combination competes across two distinct markets.
U.S. hospital market
The main competitors include:
- OFIRMEV, an IV acetaminophen product associated with Mallinckrodt
- Caldolor, an IV ibuprofen product associated with Cumberland Pharmaceuticals
- Generic IV acetaminophen
- Generic IV ibuprofen
- Oral or enteral acetaminophen and NSAID therapy
- Opioids and regional anesthesia approaches
The combination’s commercial argument is reduced administration burden and potentially improved pain control compared with either ingredient alone. Hospitals may still prefer lower-cost single agents, especially when a patient can receive oral medication.
Consumer-health market
The oral combination competes with:
- Haleon’s Advil Dual Action
- AFT Pharmaceuticals’ Maxigesic products
- Generic acetaminophen and ibuprofen combinations
- Separate OTC acetaminophen and ibuprofen products
- Aspirin-containing analgesics
- Naproxen products
The consumer market is larger in volume but more exposed to price competition, private-label products, retailer bargaining power and advertising costs.
How does Combogesic IV compare with OFIRMEV and Caldolor?
| Product |
Active ingredient |
Main advantage |
Main commercial weakness |
| Combogesic IV |
Acetaminophen plus ibuprofen sodium |
Two non-opioid mechanisms in one product |
Higher formulation and acquisition complexity |
| OFIRMEV |
IV acetaminophen |
Established hospital use and familiar safety profile |
No NSAID component |
| Caldolor |
IV ibuprofen |
Anti-inflammatory NSAID activity |
No acetaminophen component and NSAID restrictions |
| Generic IV products |
Single-agent acetaminophen or ibuprofen |
Lower price |
Separate administration and potential workflow burden |
Combogesic IV is most differentiated where hospitals value multimodal analgesia and simplified administration. It is less differentiated when procurement decisions are based almost entirely on unit price.
What market dynamics will determine sales growth?
Opioid-sparing protocols
The strongest demand driver is continued adoption of multimodal pain management. Hospitals use combinations of acetaminophen, NSAIDs, regional anesthesia and other non-opioid interventions to reduce opioid use after surgery.
The combination may benefit when clinicians want both acetaminophen and NSAID activity but do not want to administer two separate IV products.
Oral-to-IV conversion
The addressable market is limited to patients who require intravenous therapy. Once patients can tolerate oral medication, hospitals generally have an incentive to switch to less expensive oral products.
This creates a natural ceiling on duration of therapy and revenue per patient.
Hospital procurement
Hikma’s established injectable sales infrastructure is commercially important. The product requires hospital sales coverage, pharmacy engagement, distribution and formulary contracting. A successful launch depends less on consumer advertising and more on account-level adoption.
Supply and manufacturing
Sterile injectable shortages can create temporary demand for alternative products, but shortages can also affect the combination itself. Commercial reliability depends on active pharmaceutical ingredient supply, sterile filling capacity, quality compliance and inventory management.
Pricing pressure
The product cannot rely on ingredient novelty to support premium pricing. Hospital buyers can compare it with generic IV agents and separate oral therapy. Net pricing will reflect contracting, rebates, wholesaler terms and group purchasing agreements.
What is the financial trajectory for acetaminophen and ibuprofen sodium?
Public companies have not disclosed a complete standalone revenue series for the U.S. IV combination. Hyloris reports broader product and portfolio information, while Hikma reports larger business segments rather than product-level Combogesic IV revenue.[3][4]
The likely financial trajectory has four phases:
| Phase |
Financial characteristics |
| Launch |
Low revenue, high regulatory, launch and market-access costs |
| Formulary expansion |
Rising volume as hospitals add the product to protocols |
| Contract maturation |
Lower net price but greater account penetration |
| Generic pressure |
Slower growth or declining price if equivalent injectables enter |
The initial revenue opportunity is likely to be driven by hospital account additions rather than broad patient volume. Gross margin should be higher than for commodity oral analgesics if the product maintains differentiated pricing, but injectable manufacturing and hospital distribution costs reduce margin relative to a simple branded tablet.
Hyloris benefits through product economics and partnership arrangements, while Hikma captures value through commercialization and injectable infrastructure. The economic split depends on licensing, supply and milestone agreements that are not fully disclosed in public product-level reporting.[3][4]
What revenue exposure does the product create for Hyloris and Hikma?
For Hyloris, the combination is one component of a broader portfolio of reformulated and differentiated medicines. Its financial importance depends on whether it reaches meaningful U.S. hospital penetration and whether international partners commercialize related products.
For Hikma, Combogesic IV fits within the Injectables segment. The product can add incremental revenue without requiring Hikma to build a new hospital sales channel. Its contribution is unlikely to be material to consolidated company revenue unless it achieves broad formulary adoption or expands into multiple markets.
The commercial model reduces launch risk for the developer but also limits direct control over pricing, sales execution and account prioritization.
Which companies are challenging the product with generics?
No widely reported, product-specific U.S. Paragraph IV litigation involving Combogesic IV has established a major generic challenge in the public record cited here. That does not eliminate future ANDA or patent risk.
A generic competitor would likely evaluate:
- Whether the product has Orange Book-listed patents
- Whether the applicant can challenge those patents under Paragraph IV
- Whether a non-infringing formulation can be developed
- Whether the IV combination is pharmaceutically equivalent
- Whether the market is large enough to justify injectable development
- Whether hospital contracts are accessible after approval
A first generic could face technical barriers but still pressure net pricing quickly if hospitals treat the product as a procurement item rather than a clinically indispensable therapy.
What litigation and settlement risks affect the product?
The most relevant legal risks are potential patent litigation against an ANDA applicant, disputes over formulation or process patents, and commercial disputes involving licensing or supply arrangements.
A standard Paragraph IV challenge could generate:
- A 30-month stay of FDA approval in certain circumstances
- Patent infringement litigation in federal court
- Launch-at-risk exposure
- A possible license or delayed-entry settlement
- Entry dates tied to patent expiration or settlement terms
No publicly established settlement agreement has defined U.S. generic entry for the combination in the cited sources. The absence of a reported settlement leaves the timing of future competition dependent on patent listings, litigation and regulatory review.
Is there biosimilar risk for acetaminophen and ibuprofen sodium?
Biosimilar risk is not applicable. Acetaminophen and ibuprofen sodium are small-molecule active ingredients, not biologics.
The relevant competitive pathway is generic substitution through ANDA approval or, for certain differentiated products, a 505(b)(2) application. A 505(b)(2) applicant could rely partly on existing safety and efficacy data while pursuing a different formulation, route or dosage form.
What generic launch scenarios exist?
Three launch scenarios are commercially plausible.
Scenario 1: Slow generic entry
A generic developer faces formulation complexity, limited market size and an uncertain patent estate. The branded product retains premium pricing, but growth remains modest.
Scenario 2: Single generic entrant
One approved injectable competitor enters through a hospital contract. Net pricing declines, although the branded product retains some accounts through supply reliability and contracting.
Scenario 3: Multiple generic entrants
Several manufacturers enter after patent barriers weaken. The product becomes a price-sensitive injectable, with revenue shifting from price to volume. The branded combination may retain a niche if hospitals value the single-container workflow.
How does the international market compare with the U.S. market?
International oral-market economics are broader in patient reach but more fragmented. AFT has commercialized Maxigesic products across multiple countries, with formulations and regulatory approvals varying by jurisdiction.[5]
| Market |
Commercial profile |
| United States IV |
Hospital-focused, formulary-driven and technically difficult to manufacture |
| United States oral |
Retail-focused, crowded and price competitive |
| Europe |
Country-specific reimbursement, pharmacy and OTC rules |
| Australia and New Zealand |
Established AFT presence and consumer-health positioning |
| Emerging markets |
Volume opportunity but greater pricing and regulatory variability |
Geographic protection depends on local formulation patents, regulatory approvals, trademarks and partner agreements. Patent expiry in one jurisdiction does not establish freedom to operate in another.
Key Takeaways
- The U.S. product is an IV fixed-dose combination of 1,000 mg acetaminophen and 300 mg ibuprofen sodium.
- FDA approval supports acute pain and fever treatment when intravenous administration is appropriate.[1]
- The commercial opportunity is concentrated in hospitals and surgery-related care.
- Product differentiation comes from formulation, administration convenience and multimodal analgesia, not from novel active ingredients.
- OFIRMEV, Caldolor, generic IV products and oral analgesics create substantial substitution pressure.
- Hyloris and Hikma have not disclosed a complete standalone revenue history for Combogesic IV.
- The patent estate is likely formulation- and manufacturing-focused, making it weaker than a new-molecule patent estate.
- Biosimilar competition is irrelevant; generic and 505(b)(2) pathways are the primary threats.
- Revenue growth depends on formulary adoption, hospital contracting, supply reliability and opioid-sparing protocols.
- Long-term pricing risk is moderate to high because the active ingredients are mature and generic.
FAQs
Is acetaminophen and ibuprofen sodium the same as Advil Dual Action?
No. Advil Dual Action is an oral consumer product containing acetaminophen and ibuprofen. Combogesic IV is an intravenous formulation using acetaminophen and ibuprofen sodium for hospital use.
Can a generic manufacturer copy Combogesic IV?
A generic manufacturer may pursue an ANDA if it can demonstrate pharmaceutical equivalence, bioequivalence where applicable and compliance with injectable manufacturing requirements. Patents listed for the reference product may delay or complicate approval.
Does the combination reduce opioid use?
It is positioned for multimodal, opioid-sparing pain management. Its actual impact depends on hospital protocols, patient characteristics and whether clinicians use it instead of opioids or instead of separate non-opioid agents.
Is ibuprofen sodium protected by a new chemical entity patent?
No commercially significant new chemical entity protection exists for ibuprofen sodium. Any remaining protection would arise from the specific combination, formulation, manufacturing process or method of use.
What is the largest financial risk for the product?
The largest risk is limited hospital adoption caused by price competition from generic single-agent IV products and substitution with oral analgesics once patients can tolerate oral treatment.
References
- U.S. Food and Drug Administration. (2023). Combogesic IV prescribing information.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Hyloris Pharmaceuticals. (2024). Annual report 2023.
- Hikma Pharmaceuticals PLC. (2024). Annual report 2023.
- AFT Pharmaceuticals. (2024). Annual report 2024.
